Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SR 49059

Known as: SR-49059, SR49059 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

relcovaptan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Mice Heterozygous for the Oxytocin Receptor Gene (Oxtr+/−) Show Impaired Social Behaviour but not Increased Aggression or Cognitive Inflexibility: Evidence of a Selective Haploinsufficiency Gene…
We characterised the behavioural phenotype of mice heterozygous (Oxtr+/−) for the oxytocin receptor gene (Oxtr) and compared it… Expand
Highly Cited
2010
Highly Cited
2010
Increased vasopressin transmission from the paraventricular nucleus to the rostral medulla augments cardiorespiratory outflow in chronic intermittent hypoxia‐conditioned rats
A co‐morbidity of sleep apnoea is hypertension associated with elevated sympathetic nerve activity (SNA) which may result from… Expand
Highly Cited
2007
Highly Cited
2007
Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Intracellular retention of a functional vasopressin V2 receptor (V2R) is a major cause of congenital nephrogenic diabetes… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2006
Highly Cited
2006
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
In many mendelian diseases, some mutations result in the synthesis of misfolded proteins that cannot reach a transport-competent… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2006
Highly Cited
2006
Vasopressin Inhibits Glutamate Release via Two Distinct Modes in the Brainstem
The hypothalamus coordinates autonomic responses in part through arginine vasopressin (AVP) released in medial nucleus tractus… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2004
Highly Cited
2004
Pharmacochaperones Post-translationally Enhance Cell Surface Expression by Increasing Conformational Stability of Wild-type and Mutant Vasopressin V2 Receptors*
Some membrane-permeable antagonists restore cell surface expression of misfolded receptors retained in the endoplasmic reticulum… Expand
Highly Cited
2004
Highly Cited
2004
Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.
In most cases, nephrogenic diabetes insipidus results from mutations in the V2 vasopressin receptor (V2R) gene that cause… Expand
Highly Cited
2003
Highly Cited
2003
Vasopressin Differentially Modulates Non-NMDA Receptors in Vasopressin and Oxytocin Neurons in the Supraoptic Nucleus
Magnocellular neurons of the supraoptic nucleus release the neuropeptides oxytocin and vasopressin from their dendrites to… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2002
Highly Cited
2002
Effects of Nonpeptide V1 Vasopressin Receptor Antagonist SR-49059 on Infarction Volume and Recovery of Function in a Focal Embolic Stroke Model
Background and Purpose— Cerebral edema develops very early after the onset of focal cerebral ischemia and may be a major factor… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Highly Cited
1993
Highly Cited
1993
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
SR 49059, a new potent and selective orally active, nonpeptide vasopressin (AVP) antagonist has been characterized in several in… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE